ST-501 / Sangamo Therap - LARVOL DELTA

Molecular epidemiology of extended-spectrum beta-lactamase-producing-Klebsiella species in East Tennessee dairy cattle farms. (PubMed, Front Microbiol) - "The most frequently occurring STs were ST353 (n = 8), ST469 (n = 6), and the novel ST7501 (n = 6)...The high burden and dual spread mechanism of ESBL genes in Klebsiella species, combined with the emergence of novel sequence types, could swiftly increase the prevalence of ESBL-Klebsiella spp., posing significant risks to human, animal, and environmental health. Immediate action is needed to implement rigorous surveillance and control measures to mitigate this risk."

Journal • Infectious Disease • Pneumonia

Comprehensive whole genome analysis of Staphylococcus aureus isolates from dairy cows with subclinical mastitis. (PubMed, Front Microbiol) - "The 38 isolates were grouped by the in silico multi-locus sequencing types (MLST) into seven sequence types (STs), that is (ST 97, 352, 152, 243) and three new STs (ST8495, ST8500, and ST8501)...Surprisingly, no methicillin resistance associated genes were detected in these isolates. Genome data of the current study will contribute to understanding epidemiology S. aureus genotypes and ultimately aid in developing treatment and control plans to stop the spread of mastitis in the Free State province and South Africa as a whole."

Journal

Three novel sequencing types from seventeen Staphylococcus aureus genomes isolated from dairy cows milk in the Free State Province of South Africa. (PubMed, Microbiol Resour Announc) - "Staphylococcus aureus is one of the major pathogens causing bovine mastitis, which results in huge economic losses in the dairy industry worldwide. Here, we report genome sequences of 17 S. aureus strains, with three novel sequencing types (ST8495, ST8500, and ST8501) isolated from the milk of dairy cows with subclinical mastitis."

Journal

Sclerotioloids A-C: Three New Alkaloids from the Marine-Derived Fungus Aspergillus sclerotiorum ST0501. (PubMed, Mar Drugs) - "Alkaloids, as one of the largest classes of natural products with diverse structures, are an important source of innovative medicines. Sclerotioloid B (2) showed the inhibition of NO production induced by lipopolysaccharide (LPS), with an inhibition rate of 28.92% higher than that of dexamethasone (25.87%). These results expanded the library of fungal-derived alkaloids and further prove the potential of marine fungi in the generation of alkaloids with new scaffolds."

Journal

Non-lactose fermenting Escherichia coli: Following in the footsteps of lactose fermenting E. coli high-risk clones. (PubMed, Front Microbiol) - "The most prevalent sequence types (STs) were ST131 (23%), ST1193 (18%), ST12 (18%), ST501 (12%), ST167 (6%), ST73 (6%) and ST12 (6%)...We suggest that non-lactose fermenting E. coli be considered equally capable as lactose fermenting forms in causing intestinal and extraintestinal infections. Further, there is a need to undertake systematic, unbiased monitoring of predominant lineages amongst non-lactose fermenting E. coli that would help in better treatment and prevention strategies."

Journal • Hematological Disorders • Infectious Disease

Markedly Increasing Antibiotic Resistance and Dual Treatment of Neisseria gonorrhoeae Isolates in Guangdong, China, from 2013 to 2020. (PubMed, Antimicrob Agents Chemother) - "High resistance to penicillin (53.80 to 82%), tetracycline (88.30 to 100%), ciprofloxacin (96 to 99.8%), cefixime (6.81 to 46%), and azithromycin (8.60 to 20.03%) was observed...Moreover, the rates of azithromycin resistance combined with decreased susceptibility to ceftriaxone and cefixime reached 9.28% and 8.64%, respectively. Furthermore, genotyping identified NG-STAR-ST501, NG-MAST-ST2268, and MLST-ST7363 as the sequence types among representative multidrug-resistant isolates...The results showed that all the representative isolates could be effectively killed with the coadministration of less than 1 mg/liter azithromycin and 0.125 mg/liter extended-spectrum cephalosporin, with a synergistic effect according to a fractional inhibitory concentration (FIC) of <0.5. In conclusion, dual therapy might be a powerful measure to treat refractory N. gonorrhoeae in the context of increasing antibiotic resistance in Guangdong, China."

Journal • Infectious Disease

Migration of Escherichia coli and Klebsiella pneumoniae Carbapenemase (KPC)-Producing Enterobacter cloacae through Wastewater Pipework and Establishment in Hospital Sink Waste Traps in a Laboratory Model System. (PubMed, Microorganisms) - "Following inter-sink transfer, KPC-producing E. cloacae ST501 successfully integrated into the microbiome of the recipient sink and was detected in the waste trap water at least five months after the backflow event. Seven weeks and three months after the backflow, other inter-sink transfers involving Escherichia coli ST5295 and KPC-producing E. cloacae ST501 were also observed."

Clinical • Journal • Infectious Disease • Pneumonia

Genomic Medicine: Slowly Moving To All At Once (SeekingAlpha) - "Sangamo has partnered with Biogen, Novartis, Pfizer (PFE), and Takeda (TAK) to pursue up to 17 diseases using its gene regulation platform. The first of these to reach human clinical trials is likely to be ST-501 for Alzheimer’s disease, followed by ST-502 for Parkinson’s disease, based on guidance from both partners that they expect to file INDs in 2021 and 2022."

IND • New trial • Alzheimer's Disease • CNS Disorders • Parkinson's Disease

Evaluation of antifungal effect and toxicity of xanthyletin and two bacterial metabolites against Thai isolates of Pythium insidiosum. (PubMed, Sci Rep) - "In this study, xanthyletin and substances obtained from Pseudomonas stutzeri ST1302 and Klebsiella pneumoniae ST2501 exhibited anti-P...The hyphae of P. insidiosum treated with these three substances exhibited lysis holes on a rough surface and release of anamorphic material. Therefore, xanthyletin could be considered a promising alternative agent for treating cutaneous pythiosis in the near future."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

Biogen puts down massive $350M upfront for Sangamo preclinical assets (FierceBiotech) - "Shares shot up 40% after-hours on the news to $9.31 a share...Biogen will collaborate with Sangamo on a new gene regulation therapy approach, working at the DNA level, with the potential to treat challenging neurological diseases of global significance....Now, it’s boosting its AD and CNS pipeline further, paying a staggering $350 million upfront for a series of Sangamo’s preclinical assets with a $2.37 billion biobucks stream attached."

Licensing / partnership • Stock price

Biogen and Sangamo announce global collaboration to develop gene regulation therapies for Alzheimer’s, Parkinson’s, neuromuscular, and other neurological diseases (Biogen Press Release) - "Biogen Inc....today announced that they have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets."

Licensing / partnership